Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sanofi Pasteur receives EU paediatric vaccine approval

Sanofi Pasteur receives EU paediatric vaccine approval

22nd April 2013

Sanofi Pasteur has announced that its new six-in-one paediatric vaccine Hexyon has been approved for sale by the European Commission.

The product has been ratified as the only fully liquid ready-to-use vaccine that protects infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive infections caused by haemophilus influenzae type B.

Intended for primary and booster vaccination of infants from six weeks of age, the drug is being commercialised under the name Hexyon in western Europe and as Hexacima in eastern European nations.

By combining six vaccines in one, the product reduces the number of required injections, which improves comfort and vaccination compliance for infants.

Olivier Charmeil, president and chief executive officer of Sanofi Pasteur, said: "We will introduce the Hexyon/Hexacima vaccine in countries that are looking for improved and effective solutions for public immunisation programs."

Earlier this month, the company's new quadrivalent flu vaccine was accepted for European regulatory review.ADNFCR-8000103-ID-801574675-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.